Stock AMGN AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Amgen Inc. Buenos Aires S.E.

Equities

AMGN

ARDEUT110665

End-of-day quote Buenos Aires S.E.
Other stock markets
 23:00:00 21/05/2024 BST 		5-day change 1st Jan Change
12,890 ARS +2.77% Intraday chart for Amgen Inc. +10.48% +38.11%
05-22 Sandoz: Marketing authorization for Wyost and Jubbonti in the EU CF
05-22 Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test MT

Evolution of the average Target Price on Amgen Inc.

Price target over the last 5 years

History of analyst recommendation changes

718294c76.iL59Eh09g0WGfT3WNVyyCOoG3DZ8n_2F0YqJKFNH68w._s8zfStL0wK0L0qGBG3xZY52rV0u6cvOpMHiQDxqspTck04nVHmxJ_EabA~96d0f01225c46e9fa45fb1c3451abf66

Analyst Recommendations on Amgen Inc.

HSBC Adjusts Price Target on Amgen to $356 From $322 MT
Redburn Adjusts Price Target on Amgen to $170 From $180, Keeps Sell Rating MT
ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive... Our Logo
Redburn Atlantic Adjusts Price Target on Amgen to $180 From $170 MT
Mizuho Securities Raises Amgen's Price Target to $235 From $223 MT
North American Morning Briefing : Stock Futures -2- DJ
UBS Adjusts Price Target on Amgen to $307 From $284, Maintains Neutral Rating MT
Deutsche Bank Adjusts Price Target on Amgen to $310 From $285, Hold Rating Maintained MT
William Blair Upgrades Amgen to Outperform From Market Perform MT
Leerink Adjusts Price Target on Amgen to $352 From $324, Keeps Market Perform Rating MT
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data RE
Barclays Upgrades Amgen to Equalweight From Underweight, Adjusts Price Target to $300 From $230 MT
Morgan Stanley Adjusts Price Target on Amgen to $310 From $271, Keeps Equalweight Rating MT
RBC Adjusts Price Target on Amgen to $328 From $332, Keeps Outperform Rating MT
BMO Capital Adjusts Price Target on Amgen to $355 From $336, Keeps Outperform Rating MT
Goldman Sachs Adjusts Price Target on Amgen to $350 From $359, Keeps Buy Rating MT
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna... Our Logo
UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating MT
TD Cowen Cuts Price Target on Amgen to $360 From $370, Buy Rating Kept MT
Goldman Sachs Adjusts Amgen Price Target to $359 From $361, Maintains Buy Rating MT
BMO Lowers Price Target on Amgen to $336 From $343 MT
Morgan Stanley Cuts Price Target on Amgen to $271 From $278, Keeps Equalweight Rating MT
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... Our Logo
Fed officials fail to convince investors, who are focused on earnings Our Logo
Oppenheimer Adjusts Amgen Price Target to $380 From $350, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
309.4 USD
Average target price
316.1 USD
Spread / Average Target
+2.15%
High Price Target
380 USD
Spread / Highest target
+22.81%
Low Price Target
170 USD
Spread / Lowest Target
-45.06%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Amgen Inc.

HSBC
Redburn Atlantic
Mizuho Securities
UBS
Deutsche Bank Securities
William Blair & Co.
Leerink Partners
Barclays
Morgan Stanley
RBC Capital Markets
BMO Capital
Goldman Sachs
TD Cowen
Oppenheimer
Baird
Daiwa Securities
Truist Securities
Argus
Jefferies & Co.
Credit Suisse
DA Davidson
Piper Sandler
Wells Fargo Securities
SVB Securities LLC
Cowen
Atlantic Equities
BofA Securities
SVB Leerink
JPMORGAN Cory Kasimov
RBC Kennen Mackay

Ratings for Amgen Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. AMGN Stock
  5. Consensus Amgen Inc.